Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
158 Results for "
tumor development
" in MedChemExpress (MCE) Product Catalog:
Products (158)
158 Results for "tumor development" in MCE Product Catalog:
Cat. No.: HY-W142432S
Cat. No.: HY-186233
Research Areas:
CS-1-174 is a biotin-modified probe derived from KCC-07 (HY-131031), with specific binding activity to enrich MBD2. CS-1-174 captures MBD2 in cell lysates via pull-down by binding streptavidin magnetic beads through its terminal biotin tag. CS-1-174 serves as a functional tool probe in the development of TRACER technology, and is used to verify the target binding ability of MBD2 in tumor cells .
Cat. No.: HY-P10417B
Cat. No.: HY-L169
706 compounds
Resistance refers to the decrease in the effectiveness of drugs in treating diseases or symptoms. Due to the increasing global antibiotic resistance, it may threaten our ability to treat common infectious diseases. Drug resistance is also the main cause of chemotherapy failure in malignant tumors. In approximately 50% of cases, drug resistance exists even before chemotherapy begins. There are many mechanisms of anticancer drug resistance, including increased protein expression that leads to drug removal, mutations in drug binding sites, recovery of tumor protein production, and pre-existing genetic heterogeneity in tumor cell populations. In addition, the issue of drug resistance seems to have affected the development of new anticancer drugs. Drug resistance may be caused by various conditions, such as mutations, epigenetic modifications, and upregulation of drug efflux protein expression. Overcoming multidrug resistance in cancer treatment is becoming increasingly important.
MCE designs a unique collection of 706 anti-drug-resistant compounds. It is a good tool to be used for research on cancer and other diseases.
Cat. No.: HY-122224
CAS No.: 1590379-85-3
Target:
Research Areas:
SW43 is a Sigma-2 selective ligand and agonist. SW43 is an ideal molecule for the development of cancer-targeted drug compounds. SW43 conjugated with DOX-L-NETA ( 89Y) exhibits antitumor activity in a VX2 cancer liver tumor allograft rabbit model. SW 43 conjugated with SW IV-52s to form SW III-123 activates the NF-κB pathway, has potent cytotoxicity against ovarian cancer cell lines, and induces apoptosis .
Cat. No.: HY-155781
CAS No.: 3052814-78-2
Target:
Research Areas:
Anti-inflammatory agent 53 (compound 7c) is an orally active selective COX-2 inhibitor. Anti-inflammatory agent 52 has anti-HT29 transfer activity, which leads to periodic arrest in S phase and G2/M phase. Anti-inflammatory agent 52 has safety, moderate ability to suppress inflammation. Anti-inflammatory agent 52 has a rare property of suppressing the development of tumor in mouse model, showing anti-cancer activity .
Cat. No.: HY-B0281AR
CAS No.: 66357-59-3
Research Areas:
Ranitidine hydrochloride (Standard) is the analytical standard of Ranitidine hydrochloride (HY-B0281A). This product is intended for research and analytical applications. Ranitidine hydrochloride is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine hydrochloride antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA2 values of 7.2 and 6.95, respectively. Ranitidine hydrochloride inhibits breast tumor development and spread in mice.
Cat. No.: HY-B0281AS
CAS No.: 1185238-09-8
Cat. No.: HY-B0693S
CAS No.: 1185514-83-3
Cat. No.: HY-W587468
CAS No.: 4159-20-0
Synonyms: 3,4-DHRA
Cat. No.: HY-113081R
CAS No.: 15763-06-1
Cat. No.: HY-W115607
CAS No.: 24991-53-5
Synonyms: Poly(ethylene glycol)-bis-amine 4000
Cat. No.: HY-143616
CAS No.: 2659225-28-0
Target:
Research Areas:
EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) .
Cat. No.: HY-161824
CAS No.: 2913194-20-2
Target:
Research Areas:
Antiproliferative agent-52 is a tubulin inhibitor with a porcine tubulin KD of 29.65 μM. Antiproliferative agent-52 binds to the colchicine-binding site at the α-tubulin and β-tubulin interface and inhibits tubulin polymerization. Antiproliferative agent-52 exhibits antiproliferative activity against tumor cells. Antiproliferative agent-52 serves as a lead compound for development of thienopyrimidine and heterocyclic fused pyrimidines with antiproliferative activity. Antiproliferative agent-52 can be used for the research of ovarian cancer, non-small cell lung cancer .
Cat. No.: HY-B0006CS
CAS No.: 2747915-92-8
Synonyms: (R)-BM 14190-d4
Cat. No.: HY-L188
2,134 compounds
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets.
MCE designs a unique collection of 2,134 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
Target:
Lactonic sophorolipid is an apoptosis inducer and antimicrobial surfactant with antitumor activity. Lactonic sophorolipid regulates Bax/Bcl-gene expression through caspase-3/9 and induces apoptosis in tumor cells. Lactonic sophorolipid can disrupt cell membrane permeability and exert antibacterial effects (MIC for oral pathogens is 100-400 μg/mL). Lactonic sophorolipid promotes mitochondrial membrane potential depolarization, activates the intrinsic apoptotic pathway, and can synergize with antibiotics to enhance the antibacterial effect. Lactonic sophorolipid can be used in liver cancer research and the development of oral hygiene antibacterial agents[1][2][3].
Cat. No.: HY-181840
CAS No.: 1846587-13-0
Target:
Research Areas:
MU262 is a MUS81 inhibitor with an IC50 value of 0.87 μM. MU262 directly inhibits the catalytic activity of MUS81 without interfering with DNA binding, induces genomic instability in tumor cells, and specifically inhibits the HR/BIR repair pathway. The combination of MU262 with Cisplatin (HY-17394) significantly enhances the chemotherapeutic killing effect. MU262 serves as a chemical biology tool for studying MUS81 function, and also acts as a lead compound for the development of anticancer therapies that exploit DNA repair defects in cancer cells .
Synonyms: BRD5846
Target:
Research Areas:
BAY-888 is a selective CK1α/CSNK1A1 (casein kinase 1α) ATP-competitive inhibitor (IC50: 4 nM@10 μM ATP; 63 nM@1 mM ATP). BAY-888 blocks the negative regulation of p53 and other signaling pathways by CK1α, induces apoptosis and inhibits proliferation of tumor cells. BAY-888 has shown inhibitory efficacy against cancers such as acute myeloid leukemia (AML) in PRISM barcoded cell line screening and can mimic the effects of shRNA-mediated CK1α knockdown. BAY-888 is primarily used for the development of anticancer drugs for p53 wild-type tumors and for the study of the mechanisms of CK1α-related signaling pathways .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
